CDKN1B Genotype

If you have been diagnosed with an overactive parathyroid gland or a pituitary tumor and standard genetic testing came back clean, this gene is one of the next places to look.

It is one of the causes of a rare inherited syndrome that produces tumors in hormone-making glands, and knowing your status can change how closely you and your blood relatives are watched for years.

What This Gene Does

CDKN1B (cyclin-dependent kinase inhibitor 1B) carries the blueprint for a protein called p27, which acts as a brake on the cell-division cycle. When p27 works normally, it slows cells down before they copy their DNA and split, keeping tissue growth in check.

When an inherited change weakens or shortens this protein, that brake loosens, and cells in certain glands can divide more freely and form tumors. This is why the gene behaves as a tumor suppressor, a gene whose normal job is to hold back unwanted growth. Changes to this gene have also been found inside tumor tissue itself in parathyroid growths, small-bowel neuroendocrine tumors, and a blood cancer called hairy cell leukemia, but those are changes acquired within the tumor rather than inherited, and this test looks only at the version you were born with.

Multiple Endocrine Neoplasia Type 4

The clearest reason to test this gene is a rare inherited condition called MEN4 (multiple endocrine neoplasia type 4). Inherited changes that disable one copy of the gene cause it, and the pattern is autosomal dominant, meaning a single altered copy is enough to raise risk and each child of a carrier has a one-in-two chance of inheriting it.

The most consistent feature is an overactive parathyroid gland, which pushes blood calcium up. Pituitary tumors are the next most common, and neuroendocrine tumors of the gut and pancreas occur less often. In one large family, every one of the 13 tested carriers developed high calcium from overactive parathyroids, four had pituitary tumors, and one had a carcinoid tumor that had spread.

This inherited cause is uncommon. An early study of people who looked like they had the more familiar syndrome MEN1 but tested negative for its gene found a disabling CDKN1B change in about 1 in 36 (2.8%), but that came from a small group of only 36 cases. A much larger 2024 study of about 5,600 people suspected of having MEN1 found such changes in only around 0.07%, so the true frequency is likely far below the early estimate. Either way, the syndrome it produces tends to be milder and to appear later in life than MEN1.

Childhood and Sporadic Cushing's Disease

Inherited changes in this gene have also been found in Cushing's disease, a condition where a pituitary tumor drives excess cortisol. In a group of 211 people, most of them children, with what looked like isolated, non-inherited disease, 5 carried a CDKN1B change of interest, which is about 2.6%. The takeaway is that a normal-looking family history does not fully rule out an inherited cause.

Common Variants and Cancer Risk

Separate from the rare disabling changes, this gene has two common spelling differences that many people carry: one written as V109G and one in the gene's control region written as -79C>T. These are low-penetrance, meaning they nudge risk modestly rather than causing disease outright, and the direction and size of the effect differ from one disease to the next. Treat the numbers below as exploratory signals, not verdicts.

Sources: Driver et al. 2008 and Ma et al. 2006 (breast cancer); Kibel et al. 2003 (prostate cancer); Ruggiero et al. 2025 (colorectal cancer).

What this means for you: these common variants are far weaker signals than the rare disabling changes that cause MEN4, and they are not used to diagnose anything on their own. The prostate cancer link in particular has not held up consistently, with several later studies finding no association or even a protective effect, and pooled analyses of the breast cancer variant show smaller effects than any single study. Whether your test even reports these variants depends on the specific panel used, which is worth confirming before reading much into a result.

Why the Same Variant Points Both Ways

The V109G variant looks harmful in some cancers and protective in others, which can be confusing. In colorectal and prostate cancer, carriers fared worse, but in medullary thyroid carcinoma, a cancer of the thyroid's calcitonin-making cells, carriers were more likely to reach biochemical remission while people with the ordinary spelling had more recurrence and spread. This is not a simple good-number or bad-number marker. Its meaning depends on the tissue and the tumor type, so a single reading cannot be read as broadly good or bad for your health.

A Result That Does Not Change

Because this is the DNA sequence you were born with, it is a once-in-a-lifetime test. The result is permanent and does not need to be repeated, unless a lab wants to confirm an unexpected finding with a second method. The value comes not from retesting the gene but from acting on the answer over many years.

If you carry a disabling variant, the tracking that matters is of the glands themselves. That means periodic checks of blood calcium and parathyroid hormone, pituitary hormone levels, and, when indicated, imaging of the pituitary, so that any early tumor is caught while it is small and treatable. This monitoring is ongoing even though the genetic result never changes.

What to Do With an Unexpected Result

A disabling CDKN1B variant should trigger a workup, not just a note in your file. The usual next steps are testing for the more common MEN1 gene if that has not been done, referral to an endocrinologist and a clinical geneticist, and baseline biochemical screening for an overactive parathyroid and pituitary problems. Combinations of findings drive action: a variant plus high calcium and high parathyroid hormone points toward treating primary hyperparathyroidism, while a variant with normal glands points toward watchful surveillance rather than intervention.

A positive result also changes the conversation with your family. Because the pattern is autosomal dominant, your parents, siblings, and children each have a meaningful chance of carrying the same change, and cascade testing lets relatives who test positive start surveillance before symptoms appear. A geneticist or genetic counselor can help decide who to test and when.

Limits of a Genetic Result

A genetic result can mislead in ways that have nothing to do with your biology. The most important limits to keep in mind:

• Panel coverage: the assay only detects the specific changes it is designed to find. Some disease-causing changes sit in the gene's control and start regions rather than the main coding sequence, and a test limited to coding regions can miss them, so a negative result does not rule out every possible variant.
• Ancestry and allele frequency: the common variants differ in how often they appear across populations, so the clinical meaning of a result can depend on your ancestry and is not identical for everyone.
• Uncertain variants: a change of unknown meaning, called a variant of uncertain significance, can be reported. It is not proof of disease, and how much weight to give it depends heavily on genetic counseling rather than the raw result.
• Tissue source: clinical panels assume DNA from normal cells that reflects your inherited code. Changes found only inside tumor tissue are acquired later and are not the same as an inherited result.